Skip to main content

Diabetes

  • CVS/pharmacy kicks off 2011 To Your Health program

    WOONSOCKET, R.I. — CVS/pharmacy has announced the launch of the 2011 To Your Health program, offering free preventive health screenings at more than 800 events in communities across the country. The program is designed to help Americans determine their risk for chronic diseases and get them on a path to better health.

    The program will get under way in Houston on March 5, and continue in Dallas, Los Angeles, Washington, D.C., Atlanta, Philadelphia, Chicago and Miami.

  • Fatty liver may impose diabetes risk

    NEW YORK — Over the years, a fatty liver has become an indicator of obesity and insulin resistance among humans, but researchers have found that people with fatty livers are five times more likely to develop Type 2 diabetes than their healthier counterparts.

  • Type 1 diabetics continue to be at risk for kidney disease

    BOSTON — Advances in kidney care have not led to successful efforts to improve therapy for patients with Type 1 diabetes, according to a study published in the Journal of the American Society of Nephrology.

  • Weis Lifestyle Initiatives now part of pharmacy division

    SUNBURY, Pa. — Weis Markets streamlined its internal connection between wellness and pharmacy earlier this year with an organizational restructure that folded the Weis Lifestyle Initiatives department, led by registered dietitian Karen Buch, into the grocer’s pharmacy division.

  • Study: Hemoglobin A1C may not effectively diagnose kids with diabetes

    ANN ARBOR, Mich. — A convenient blood-glucose test commonly used to diagnose diabetes and prediabetes may not be the best way to diagnose children, according to a new study.

  • Onglyza gets label update

    PRINCETON, N.J., and WILMINGTON, Del. — The makers behind a popular Type 2 diabetes treatment have included data from two clinical studies in an update to the drug's prescribing information.

    Bristol-Myers Squibb and AstraZeneca said the Food and Drug Administration approved the labeling update for Onglyza (saxagliptin), which now includes efficacy and safety information about the drug's effects on patients with renal impairment or end-stage renal disease.

  • New cardiovascular risk calculator now available online

    NEW YORK — In line with American Heart Month, Boehringer Ingelheim's Micardis has introduced a cardiovascular risk-reduction calculator, designed to assess patients' cardiovascular risk.

    The calculator, which can be accessed at MicardisPro.com, is an interactive, useful tool for healthcare professionals to assist patients in reaching their cardiovascular risk-reduction goal, the company said.

    Micardis (telmisartan) is a drug designed to treat hypertension.

  • CVS Caremark saluted for Pharmacy Advisor program

    WOONSOCKET, R.I. — CVS Caremark announced on Friday that the Pharmacy Benefit Management Institute awarded the company and its PBM client, ArcelorMittal, the 2011 Rx Benefit Innovation Award. The award recognizes the Pharmacy Advisor program, which was developed by CVS Caremark to manage costs, improve medication adherence and close gaps in care for members with diabetes.

X
This ad will auto-close in 10 seconds